At a glance
What is it—and why does it matter?
Tα1 is described as an endogenous thymus-derived peptide hormone. The study used the nCounter®SPRINT Profiler platform to measure gene expression profiles following Tα1 treatment. In this retrospective cohort, thymosin α1 given for 7 days was associated with a statistically significant rise in peripheral blood total T-cell counts (median change from 422.5/μL to 614.0/μL; P < 0.001).
Sources for this introduction: [1] [2] [3]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
Thymosin alpha 1 (Tα1) is described as a peptide hormone produced by the thymus gland.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Thymosin alpha 1 (Tα1) is a thymic peptide hormone secreted by the thymus gland”
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro. · BACKGROUND
pubmed:42345155:9779840e2d7c:9779840e2d7c
Identity
Thymosin alpha-1 (Tα-1) is characterized here as an endogenous peptide hormone that modulates immune function.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“thymosin alpha-1 (Tα-1), a key endogenous peptide hormone with immunomodulatory activity”
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. · UNLABELLED
pubmed:42295795:5fd7d6948469:5fd7d6948469
Identity
In this source, Thymosin alpha-1 (Tα1) is identified as a peptide originating from the thymus.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“We show that the thymus-derived peptide Thymosin alpha-1 (Tα1) functions as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor on neurons.”
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis. · Abstract
pubmed:42693587:23f078c95bd5:23f078c95bd5
Identity
Tα1 is described as an endogenous (naturally occurring) thymus-derived peptide.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Thymosin α-1 (Tα1), a naturally occurring thymic peptide”
Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives. · Abstract
pubmed:42641753:593fe41e0814:593fe41e0814
Identity
Tα1 is described as an endogenous thymus-derived peptide hormone.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Thymosin alpha-1 (Tα1), a peptide hormone produced by the thymus,”
Aging and Thymosin Alpha-1. · Abstract
pubmed:41373628:c381abe234b4:c381abe234b4
Identity
Thymosin alpha-1 is explicitly listed as a selected peptide covered in a review of peptide interventions relevant to thyroid biology.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This review examines the mechanistic rationale for peptide interventions relevant to thyroid biology and summarizes the current state of evidence for selected peptides, including thymosin alpha-1, thymosin beta-4, BPC-157, and growth hormone secretagogues.”
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. · Abstract
pubmed:42222211:731f6d511ebf:731f6d511ebf
How does it work?
Target, response, and disposition.
Mechanism
Based on transcriptomic readouts in tumor cell lines, Tα1 was interpreted as having little-to-no transcriptional immunomodulatory activity in the tumor counterpart.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Tα1 minimally changed cancer cell DEGs and immune-related biological processes, suggesting a comprehensive lack of transcriptional immunomodulatory potential on the tumor counterpart.”
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. · RESULTS
pubmed:40955371:57f3a3b2e0c3:57f3a3b2e0c3
Mechanism
Transcriptomic and protein-level analyses are reported to show reduced PI3K/AKT pathway overactivation in hepatic CD8+T cells with the combination therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Transcriptomic and protein-level analyses revealed that the combination attenuated chronically overactivated phosphatidylinositol 3-kinase/protein kinase B signaling in hepatic CD8+T cells.”
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. · RESULTS
pubmed:41883056:1642a666ac51:1642a666ac51
Mechanism
The authors’ conclusion attributes reversal of CD8+T-cell senescence and enhanced antitumor immunity in HCC to suppression of PI3K/AKT signaling under combined IL-15 and Tα1 therapy.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Combined IL-15 and Tα1 therapy reverses CD8+T cell senescence and enhances antitumor immunity in HCC through suppression of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway.”
IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. · CONCLUSIONS
pubmed:41883056:1642a666ac51:1642a666ac51
Mechanism
Protection of miR-146a-5p by Tα-1 is linked here to enabling miR-146a-5p-driven activation of Toll-like receptor 7 (TLR7).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“allowing miR-146a-5p-mediated activation of Toll-like receptor 7 (TLR7)”
Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. · UNLABELLED
pubmed:42295795:5fd7d6948469:5fd7d6948469
Mechanism
Under the study’s in vitro exhaustion model, CD8⁺ T-cells showed increased expression of exhaustion markers PD-1, TIM-3, and LAG-3.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“In the exhaustion model, CD8⁺ T-cells exhibited overexpression of PD-1, TIM-3, and LAG-3”
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro. · RESULTS
pubmed:42345155:9779840e2d7c:9779840e2d7c
Mechanism
The study used the nCounter®SPRINT Profiler platform to measure gene expression profiles following Tα1 treatment.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“gene expression profiles were analyzed by the nCounter®SPRINT Profiler.”
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. · METHODS
pubmed:40955371:57f3a3b2e0c3:57f3a3b2e0c3
Mechanism
The abstract links Tα1–HCRTR1 engagement to reduced neuronal death via suppression of Receptor-Interacting Protein Kinase 3 (RIPK3), a necroptosis mediator.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This engagement shields neurons from cell death by suppressing the activity of Receptor-Interacting Protein Kinase 3 (RIPK3), a central executioner of necroptosis.”
Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis. · Abstract
pubmed:42693587:23f078c95bd5:23f078c95bd5
What has been studied?
What the evidence says.
Study findings
In this retrospective cohort, thymosin α1 given for 7 days was associated with a statistically significant increase in peripheral blood CD8 + T-cell counts (median 159.0/μL to 222.5/μL; P < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CD8 + T cells (159.0/μL to 222.5/μL, P < 0.001).”
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer. · Abstract
doi:10.2147/cmar.s555975:edd2a5fbc824:edd2a5fbc824
Study findings
Based on the reported results, the authors interpret the data as calling into question Tα1-mediated immunomodulation at the tumor-cell level.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Our findings question the tumor immunomodulatory properties of Tα1”
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. · CONCLUSION
pubmed:40955371:57f3a3b2e0c3:57f3a3b2e0c3
Study findings
In vitro, thymosin α-1 at 2 µM was associated with increased migratory and adhesive phenotypes in TNBC cell lines.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Conversely, CD1d upregulation by α-galactosylceramide (AGC, 2 µM) and thymosin α-1 (TA, 2 µM) promotes EMT, enhances migration and adhesion.”
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer. · Abstract
pubmed:41511636:6322595b4338:6322595b4338
Study findings
The abstract summarizes prior literature as suggesting (not proving) that Tα1 may be antitumor and may act as an adjunct that could improve responses to multiple cancer treatment modalities.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Preclinical and clinical studies suggested that Tα1 may possess antitumor activity and could enhance the efficacy of conventional and emerging cancer therapies, including chemotherapy, radiotherapy, and immune checkpoint inhibitors.”
Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives. · Abstract
pubmed:42641753:593fe41e0814:593fe41e0814
Study findings
The study generated an in vitro exhaustion model by repeatedly stimulating T-cells with CD3/CD28 prior to applying Tα1.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“T-cell exhaustion was induced by repeated CD3/CD28 stimulation before Tα1 treatment.”
Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro. · METHODS
pubmed:42345155:9779840e2d7c:9779840e2d7c
Study findings
The follow-up duration for the cohort had a median of 13.7 months, indicating the typical observation time for outcomes and adverse events.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“The median follow-up was 13.7 months.”
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer. · Abstract
doi:10.2147/cmar.s555975:edd2a5fbc824:edd2a5fbc824
Study findings
In these in-vitro tumor cell line experiments, Tα1 produced little transcriptional change as assessed by DEGs and immune-related Gene Ontology processes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Tα1 minimally changed cancer cell DEGs and immune-related biological processes, suggesting a comprehensive lack of transcriptional immunomodulatory potential on the tumor counterpart.”
The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. · RESULTS
pubmed:40955371:57f3a3b2e0c3:57f3a3b2e0c3
Study findings
In this retrospective cohort, thymosin α1 administered for 7 days was associated with a statistically significant rise in peripheral blood CD4 + T-cell counts (median 244.5/μL to 284.5/μL; P < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“CD4 + T cells (244.5/μL to 284.5/μL, P < 0.001)”
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer. · Abstract
doi:10.2147/cmar.s555975:edd2a5fbc824:edd2a5fbc824
Study findings
In this retrospective cohort, thymosin α1 given for 7 days was associated with a statistically significant rise in peripheral blood total T-cell counts (median change from 422.5/μL to 614.0/μL; P < 0.001).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Tα1 treatment for 7 days significantly increased the median counts of peripheral blood total T cells (422.5/μL to 614.0 /μL, P < 0.001)”
Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer. · Abstract
doi:10.2147/cmar.s555975:edd2a5fbc824:edd2a5fbc824
Study findings
The review characterizes the evidence base for selected peptides (including thymosin alpha-1) as mainly preclinical and mechanistic, plus early exploratory clinical reports, with a lack of large randomized trials targeting thyroid-specific outcomes.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Available data consist primarily of preclinical investigations, mechanistic studies, and early exploratory clinical reports rather than large, randomized trials focused on thyroid-specific outcomes.”
Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. · Abstract
pubmed:42222211:731f6d511ebf:731f6d511ebf
Study findings
In vitro, thymosin α-1 at 2 µM was reported to upregulate CD1d and shift cells toward an EMT phenotype in MDA-MB-468 and MDA-MB-231 models.
1 cited source · Study independence not established
Animal or laboratory findings do not establish benefit or safety in people.
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Conversely, CD1d upregulation by α-galactosylceramide (AGC, 2 µM) and thymosin α-1 (TA, 2 µM) promotes EMT, enhances migration and adhesion.”
Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer. · Abstract
pubmed:41511636:6322595b4338:6322595b4338
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Additional research & classification gaps
13 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.
Inspect contextual research (13)
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract contrasts receptor classification (HCRTR1 as a classical neuropeptide receptor) with ligand classification (Tα1 as non-canonical for that receptor).
Research context only—not evidence of a treatment effect.
- Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis.
We show that the thymus-derived peptide Thymosin alpha-1 (Tα1) functions as a non-canonical ligand for the Hypocretin (Orexin) Receptor 1 (HCRTR1), a classical neuropeptide receptor on neurons.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The combination treatment is reported to shift hepatic CD8+T-cell composition away from senescence and toward activated effector populations (no numeric changes provided).
Research context only—not evidence of a treatment effect.
- IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression.
It reduced the proportion of senescent CD8+T cells while expanding activated effector populations,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract reports emerging evidence suggesting Tα1 could increase immune-cell infiltration in tumors described as immunologically “cold,” but the claim is probabilistic (may).
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
Emerging evidence also indicates that Tα1 may improve immune infiltration in immunologically "cold" tumors
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Based on the listed immune mechanisms, the abstract proposes that Tα1 could support immune surveillance and alter the tumor microenvironment, but it is phrased as a possibility.
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
Through these actions, Tα1 may contribute to immune surveillance and modulation of the tumor microenvironment.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The described mechanism includes promoting T-cell differentiation as part of immune restoration.
Research context only—not evidence of a treatment effect.
- Aging and Thymosin Alpha-1.
It helps restore immune function by stimulating T-cell differentiation,
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Dendritic-cell functional modulation is listed as an immune mechanism attributed to Tα1.
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
modulating dendritic cell function
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
Within dendritic cells’ endolysosomal compartment after uptake of tumor apoptotic bodies, Tα-1 associates with the apoptotic bodies and their carried microRNAs such as miR-146a-5p.
Research context only—not evidence of a treatment effect.
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
Tα-1 bound to tumor ABs and interacted with AB-borne microRNAs, including miR-146a-5p, following the phagocytosis of ABs into the endolysosomal compartment of dendritic cells (DC).
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The authors characterize Tα-1 as a microRNA chaperone that facilitates a key limiting step in dendritic-cell licensing in the post-chemotherapy context.
Research context only—not evidence of a treatment effect.
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
These findings establish Tα-1 as a pivotal endogenous microRNA chaperone that unlocks a critical limiting step of DC licensing
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract lists increased NK-cell activity as one of the immune effects associated with Tα1.
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
enhancing natural killer cell activity
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract attributes effects of Tα1 on tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), which are immune populations in the tumor setting.
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
influencing tumor-associated macrophages and myeloid-derived suppressor cells
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The abstract attributes immunomodulatory activity to Tα1, including promotion of T-cell maturation and skewing helper T cells toward a Th1 phenotype.
Research context only—not evidence of a treatment effect.
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives.
Tα1 regulates both adaptive and innate immune responses by promoting T-cell maturation and T helper cell type 1 (Th1) polarization
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
In this pathway, miR-146a-5p-driven TLR7 signaling is linked to dendritic-cell licensing—maturation, trafficking to tumor-draining lymph nodes, and tumor-antigen presentation—culminating in activation of tumor-specific CD8+ T cells.
Research context only—not evidence of a treatment effect.
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells.
that licenses DC maturation, migration to tumor-draining lymph nodes, and presentation of tumor antigens to activate tumor-specific CD8+ T cells.
1 cited source · Study independence not established
How to read this evidence
Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.
1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.
The described immunomodulatory mechanism includes modulation of dendritic cells and macrophages.
Research context only—not evidence of a treatment effect.
- Aging and Thymosin Alpha-1.
and modulating dendritic cell and macrophage activity.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, interaction, regulatory, safety
- 304 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (167), assurance_score_below_0.72 (125), current_regulatory_source_required (97), extraction_ambiguity (179), high_risk_requires_regulatory_or_two_independent_sources (135), no_direct_support (291), proposal_not_staged (5)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Thymosin α1 Elevates Lymphocyte Counts and Improves Immunoradiotherapy Outcomes in Patients with Advanced Cancer. ↗
doi · published 2025-11-19 · retrieved 2026-09-04T22:25:16Z
- The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. ↗
pubmed · published 2025-01-01 · retrieved 2026-08-30T08:40:08Z
- Aging and Thymosin Alpha-1. ↗
pubmed · published 2025-11-27 · retrieved 2026-08-30T08:40:08Z
- Zerumbone mediated CD1d inhibition suppresses epithelial to mesenchymal transition in triple negative breast cancer. ↗
pubmed · published 2026-01-09 · retrieved 2026-08-30T08:40:08Z
- IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. ↗
pubmed · published 2026-05-01 · retrieved 2026-08-30T08:40:08Z
- Peptide Therapies in Thyroid Health: Emerging Applications in Endocrine and Immune Modulation. ↗
pubmed · published 2026-04-01 · retrieved 2026-08-30T08:40:08Z
- Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. ↗
pubmed · published 2026-09-02 · retrieved 2026-09-07T08:44:20Z
- Thymosin α1 Augments CD8⁺ T-Cell Activation and Reverses Exhaustion In Vitro. ↗
pubmed · published 2026-06-01 · retrieved 2026-08-30T08:40:08Z
- Thymosin α-1 in Cancer Therapy: Immunomodulatory Mechanisms, Clinical Applications, and Translational Perspectives. ↗
pubmed · published 2026-08-25 · retrieved 2026-08-30T08:40:08Z
- Thymosin Alpha-1 Provides Direct Neuroprotection by Engaging the Orexin Receptor HCRTR1 to Suppress Neuronal Necroptosis. ↗
pubmed · published 2026-09-03 · retrieved 2026-09-07T08:44:20Z
Publication history and provenance
Version 2 · Automated assessment · 2026-09-09T10:52:55Z
1051acddd1e6d9f48c317694f4696fb95e464f4baa40e4c7253e54698a5f090b